Hypertrophic Cardiomyopathy (HCM) Therapeutics Market with a CAGR of 1.4% Expected to Be Achieved Between 2015 and 2023
The global hypertrophic cardiomyopathy (HCM) therapeutics market has been anticipated in a report penned by Transparency Market Research (TMR) to witness the dominance of industry players with a high sales rate. With that mentioned, generic players could make their presence known in the market but at a gradual pace. Leading players, viz. Merck & Co., Pfizer, Inc., and Sanofi S.A., have been foretold to account for a majority of the market share, which could reveal the significantly consolidated nature of...
View full press release